Identification and Mechanism of ABA Receptor Antagonism

Karsten Melcher $^{1\S*}$, Yong Xu $^{1*}$, Ley-Moy Ng $^{1,2*}$, X. Edward Zhou $^{1*}$, Fen-Fen Soon $^{1,2*}$, Viswanathan Chinnusamy$^{3,4}$, Kelly M. Suino-Powell $^{1}$, Amanda Kovach $^{1}$, Fook S. Tham $^{3}$, Sean R. Cutler $^{4}$ Jun Li $^{1\ 2}$, Eu-Leong Yong$^{2}$, Jian-Kang Zhu $^{4,5}$, and H. Eric Xu $^{1\S}$

Supplementary Information
Supplementary Figure 1 Pyrabactin functions both as a selective ABA receptor agonist and antagonist. (a) Stimulation of the interactions between PYR1–PYL6 and the PP2Cs ABI2 and HAB1 by pyrabactin. Binding was determined by AlphaScreen assays (n=3, error bars=s.d.). (b) Pyrabactin-dependent inhibition of ABI2 and HAB1 phosphatase activities by PYL proteins (n=3, error bars=s.d.). (c) Pyrabactin is a PYR1 agonist in an Arabidopsis protoplast reporter gene assay. Expression plasmids for PYR1, ABI1, SnRK2.6, and the transcription factor ABF2 were cotransfected into protoplasts together with a luciferase reporter plasmid driven from the ABA-responsive RD29B gene (n=3, error bars=s.d.).
Supplementary Figure 2  Structures of pyrabactin complexes and apo pyrabactin. (a) Overlay of the PYL1–pyrabactin–ABI1 and the PYL1–ABA–ABI1 structure. The PYL1–pyrabactin–ABI1 complex is shown in green (PYL1), grey (pyrabactin and ABI1 Trp300), and yellow (ABI1), the PYL1–ABA–ABI1 complex is shown in pale blue (PYL1), pink (ABA and ABI1 Trp300), and brown (AB1). (b) Pyrabactin omit maps. Simulated $F_c$–$F_c$ annealing omit maps of pyrabactin in the ligand binding pockets of PYL1 and PYL2 at 2 $\sigma$. Ligand binding residues are indicated for orientation. (c) Crystal structure of free pyrabactin at 0.7 Å resolution.
Supplementary Figure 3:

PYL2  EKOETLPVIKTYHQPFPDPPTTCTSLITQRIHAPASVWPLRREDNERKKEHVKRVRDLISGDG-----DVGSVREVTVISGLPANTSTERL
PYR1  ERSSELKNSAEFHTYQLDFGSQLLHAQRIHAPPELVWISRREDKQTYYHKYIKSCSV-----EQNF-EMRVCGRDVTVISGLPANTSTERL
PYL1  EFTQLSQSTAEFHTYQLGNGRSSLHAAQRHAPPETWSVRRFDRQTYYHKYIKSCSV-----SEDF-EMRVCGRDVTVISGLPANTSRERL

Nature Structural & Molecular Biology: doi:10.1038/nsmb.1887
**Supplementary Figure 3**  Alignment of PYR1, PYL1, and PYL2. Residues conserved within the PYR/PYL family are highlighted and ligand binding residues boxed. Red arrows indicate the three ligand binding residues that differ between PYL1 and PYL2.
Supplementary Figure 4:

- **Y-axis:** Percentage phosphatase activity
- **X-axis:** Genotypes
  - No A812
  - No PYL1
  - Wildtype
  - PYL1 A190V
  - PYL1 V193I

- **Legend:**
  - DMSO
  - 10 μM (+)-ABA
  - 100 μM pyrabactin
  - 10 μM ABA+100 μM pyrabactin

Nature Structural & Molecular Biology: doi:10.1038/nsmb.1887
**Supplementary Figure 4**  A190V and V193I enhance PYL1-mediated inhibition of ABI2 phosphatase activity by pyrabactin (n=3, error bars=s.d.).
Supplementary Figure 5:

(a) ABI2 - PYL2 A93F - pyrabactin

(b) HAB1 - PYL2 A93F - pyrabactin

(c) 

(d)
**Supplementary Figure 5**  PYL2 A93F–pyrabactin and PYL2 A93F–pyrabactin–PP2C structures.  (a) Overview of the PYL2 A93F–pyrabactin–ABI2 complex.  ABI2 is shown in yellow, its three Mg\(^{2+}\) ions in its catalytic center as grey spheres, and the locking residue Trp290 in a stick representation.  PYL2 A93F is shown in cyan with pyrabactin as ball model.  (b) Overlay of ABI2 (cyan) from the PYL2 A93F–pyrabactin–ABI2 structure with ABI1 (yellow) from the PYL1–pyrabactin–ABI1 structure and HAB1 (pink) from the PYL2–ABA–HAB1 structure.  (c) Overlay of pyrabactin (grey balls) in the PYL2 A93F–pyrabactin–ABI2 (PYL2 pink, ABI2 yellow) structure with PYL2 A93F in the PYL2 A93F–pyrabactin structure (cyan).  (d) Overview of the PYL2 A93F–pyrabactin–HAB1 complex.  HAB1 is shown in yellow, its Mg\(^{2+}\) ions in its catalytic center as grey spheres, and the locking residue Trp385 in a stick representation.  PYL2 A93F is shown in cyan with pyrabactin as ball model.
Supplementary Figure 6:

ChemBridge 8x10^5 compounds
- Substructure search: 413
- ICM/Cluster analysis
- Visual inspection: 37
- Purchased compounds: 36

ZINC8 database 1.3x10^7 compounds
- Substructure search: 4965
- Glide SP docking: Top score 500
- Visual Inspection: 50
- Purchased compounds: 28

Alpha-screen and phosphatase assay

4 actives: #32, #68, #71, #98
Supplementary Figure 6  Strategy for the identification of new ABA receptor agonists. See Result and Methods sections for details.
Supplementary Figure 7:

ABI1 binding signal

ABI2 binding signal

HAB1 binding signal

Nature Structural & Molecular Biology: doi:10.1038/nsmb.1887
Supplementary Figure 7  Screening of ABA receptor agonist candidates. AlphaScreen interaction in the presence of absence of 100 µM compound (n=3, error bars=s.d.). Note that #36 is identical to pyrabactin B, a compound identified as an ABA agonist in the same chemical genetic screen that identified pyrabactin\textsuperscript{1}.  

\[ \text{Nature Structural & Molecular Biology: doi:10.1038/nsmb.1887} \]
Supplementary Figure 8:

- **ABI1**
  - (+)-ABA
  - Pyrabactin
  - #32

- **ABI2**
  - (+)-ABA
  - Pyrabactin
  - #68
  - #71

- **HAB1**
  - (+)-ABA
  - Pyrabactin
  - #32

- **ABI2 binding signal**
- **HAB1 binding signal**

- **ABI2 binding signal**
- **HAB1 binding signal**

**Notes:**
- (+)-ABA
- Pyrabactin
- #68
- #71

*Nature Structural & Molecular Biology: doi:10.1038/nsmb.1887*
Supplementary Figure 8  Agonist dose response curves. Concentration-dependent stimulation of the interaction between PYR1 and PP2Cs by (+)-ABA, pyrabactin, and compounds #32, #68, #71, and #98 as determined by AlphaScreen assays (n=3, error bars=s.d.).
Supplementary Figure 9:

a) HAB1

b) ABI2

c) ABI1

d) PYL6

e) w/o ABA treatment

100 μM ABA (4h)
**Supplementary Figure 9** ABI1, ABI2, HAB1, and PYL6 share similar expression profiles. (a–d) Expression profiles of ABI1, ABI2, HAB1, and PYL6. Expression profiles in different plant tissues depicted as tissue heat maps. (e) ABI1, ABI2, HAB1, and PYL6 are selectively expressed in guard cells. Pictograms represent surface views of leaves with heat maps. Expression data were taken from and heat maps generated using eFP browser (http://bar.utoronto.ca).

**Supplementary Reference:**
1. Zhao, Y. et al. Chemical genetic interrogation of natural variation uncovers a molecule that is glycoactivated. *Nat Chem Biol* 3, 716-21 (2007).